Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C(CC(O)=O)C2=C1
InChI
InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N
InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)
Molecular Formula | C19H16ClNO4 |
Molecular Weight | 357.788 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:07:35 UTC 2023
by
admin
on
Fri Dec 15 15:07:35 UTC 2023
|
Record UNII |
XXE1CET956
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000000160
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-VATC |
QS01BC01
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-VATC |
QC01EB03
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
NCI_THESAURUS |
C54677
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
NDF-RT |
N0000175721
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
LIVERTOX |
NBK548001
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-ATC |
M02AA23
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
NDF-RT |
N0000175722
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-VATC |
QM01AB01
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-ATC |
M01AB01
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-ATC |
S01BC01
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-VATC |
QM02AA23
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-ATC |
S01CC02
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-VATC |
QM01AB51
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-ATC |
M01AB51
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
||
|
WHO-ATC |
C01EB03
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL6
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
DB00328
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
m6279
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | Merck Index | ||
|
5781
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | RxNorm | ||
|
D007213
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
Indomethacin
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
DTXSID9020740
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
SUB08180MIG
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
100000092758
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
49662
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
757061
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
XXE1CET956
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
1524
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
77541
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
1341001
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
3101
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
3715
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
INDOMETHACIN
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | Description: A white or a pale yellow, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS and ether R. Category: Analgesic; anti-inflammatory. Storage: Indometacin should be kept in a well-closed container, protected from light. Additional information: Indometacin exhibits polymorphism. The polymorph specified in the monograph corresponds to the crystal form of indometacin RS.Definition: Indometacin contains not less than 98.0% and not more than 101.0% of C19H16ClNO4, calculated with reference to the dried substance. | ||
|
1440
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
C576
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
53-86-1
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
1909
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
200-186-5
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY | |||
|
INDOMETACIN
Created by
admin on Fri Dec 15 15:07:35 UTC 2023 , Edited by admin on Fri Dec 15 15:07:35 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
DEGRADENT -> PARENT |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|